Biohit aktie (BIOBV) | Pressmeddelande

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2023

Cision • 09 Aug 2023 08:30

Constitutive meeting of Biohit Oyj’s Board of Directors

Cision • 15 Jun 2023 13:00

Decisions of the Annual General Meeting of Biohit Oyj

Cision • 14 Jun 2023 17:00

Notice of Biohit Oyj’s Annual General Meeting

Cision • 24 May 2023 11:00

Biohit Oyj B-shares Subscribed with Stock Options I 2021A and I 2022A

Cision • 30 Mar 2023 10:00

Publication of Biohit Oyj Renumeration Report 2022

Cision • 22 Mar 2023 08:30

Publication of Biohit Oyj Annual Report 2022

Cision • 22 Mar 2023 08:30

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2022

Cision • 15 Feb 2023 08:30

Changes to Biohit Oyj’s management: Change of R&D Director

Cision • 15 Dec 2022 13:00

Biohit Oyj - Managers' Transactions - Hendolin

Cision • 07 Dec 2022 14:00

Biohit Oyj - Managers' Transactions - Sorvo

Cision • 07 Dec 2022 14:00

Biohit Oyj’s Financial Reporting and Annual General Meeting in 2023

Cision • 30 Nov 2022 13:00

Biohit Oyj Board of Directors decided on new option scheme

Cision • 29 Nov 2022 13:00

Strong scientific Support for Biohit’s GastroPanel in International Consensus Report

Cision • 19 Sep 2022 12:00

Biohit GastroPanel enters into global market by co-operation with Randox

Cision • 07 Sep 2022 12:00

Changes to Biohit Oyj’s management

Cision • 06 Sep 2022 13:00

Change of CEO at Biohit Oyj

Cision • 02 Sep 2022 11:00

Changes to Biohit Oyj’s management

Cision • 22 Aug 2022 12:30

Dyspeptic symptoms need early attention- domestic innovations GastroPanel®, ColonView-FIT® and Acetium® will help

Cision • 09 Aug 2022 12:00

Positive profit warning: Biohit Oyj raises its guidance for 2022 and publishes preliminary information about the result of the first half-year

Positive profit warning: Biohit Oyj raises its guidance for 2022 and publishes preliminary information about the result of the first half-ye...

Cision • 03 Aug 2022 08:30

Constitutive meeting of Biohit Oyj’s Board of Directors

Cision • 16 Jun 2022 08:30

Decisions of the Annual General Meeting of Biohit Oyj

Cision • 15 Jun 2022 15:00

Notice of Biohit Oyj’s Annual General Meeting

Cision • 25 May 2022 13:00

Publication of Biohit Oyj Renumeration Report 2021

Cision • 10 May 2022 10:00

Publication of Biohit Oyj Annual Report 2021

Cision • 30 Mar 2022 08:30

Biohit Oyj Extraordinary general meeting and board of directors meeting decisions

Cision • 10 Mar 2022 09:00

NEW RECOMMENDATION BY THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION: All patients with suspected gastritis should be examined by Pepsinogen I, Pepsinogen II and Gastrin-17 biomarkers.

NEW RECOMMENDATION BY THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION: All patients with suspected gastritis should be examined by Pepsinog...

Cision • 15 Feb 2022 09:00

Notice of Biohit Oyj's extraordinary general meeting

Cision • 09 Feb 2022 13:00

Biohit has settled the dispute concerning a breach of the patent license agreement and therefore specifies its financial guidance for 2021

Cision • 08 Feb 2022 13:00

Biohit Oyj Managers' Trancactions - Elomaa

Cision • 18 Jan 2022 14:00

Biohit Oyj - Managers' Transactions - Siltala

Cision • 18 Jan 2022 14:00

Biohit Oyj - Managers' Transactions - Söderström

Cision • 18 Jan 2022 14:00

Biohit Oyj - Managers' Transactions - Patrakka

Cision • 18 Jan 2022 14:00

Biohit Oyj - Managers' Transactions - Mäki

Cision • 18 Jan 2022 14:00

Biohit Oyj - Managers' Transactions - Hahtela

Cision • 18 Jan 2022 14:00

Biohit Oyj’s Financial Reporting and Annual General Meeting in 2022

Cision • 13 Jan 2022 13:30

Recent clinical validation study confirms the accuracy of the new-generation GastroPanel® test in diagnosis of atrophic gastritis and Helicobacter pylori infection.

Recent clinical validation study confirms the accuracy of the new-generation GastroPanel® test in diagnosis of atrophic gastritis and Helico...

Cision • 14 Dec 2021 09:00

Biohit Oyj Board of Directors decided on new option scheme

Cision • 09 Dec 2021 13:00

Börskollen

För dig med koll på börsen

Pressmeddelanden från Biohit

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2023

Constitutive meeting of Biohit Oyj’s Board of Directors

Decisions of the Annual General Meeting of Biohit Oyj

Notice of Biohit Oyj’s Annual General Meeting

Biohit Oyj B-shares Subscribed with Stock Options I 2021A and I 2022A

Publication of Biohit Oyj Renumeration Report 2022

Publication of Biohit Oyj Annual Report 2022

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2022

Changes to Biohit Oyj’s management: Change of R&D Director

Biohit Oyj - Managers' Transactions - Hendolin

Biohit Oyj - Managers' Transactions - Sorvo

Biohit Oyj’s Financial Reporting and Annual General Meeting in 2023

Biohit Oyj Board of Directors decided on new option scheme

Strong scientific Support for Biohit’s GastroPanel in International Consensus Report

Biohit GastroPanel enters into global market by co-operation with Randox

Changes to Biohit Oyj’s management

Change of CEO at Biohit Oyj

Changes to Biohit Oyj’s management

Dyspeptic symptoms need early attention- domestic innovations GastroPanel®, ColonView-FIT® and Acetium® will help

Positive profit warning: Biohit Oyj raises its guidance for 2022 and publishes preliminary information about the result of the first half-year

Constitutive meeting of Biohit Oyj’s Board of Directors

Decisions of the Annual General Meeting of Biohit Oyj

Notice of Biohit Oyj’s Annual General Meeting

Publication of Biohit Oyj Renumeration Report 2021

Publication of Biohit Oyj Annual Report 2021

Biohit Oyj Extraordinary general meeting and board of directors meeting decisions

NEW RECOMMENDATION BY THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION: All patients with suspected gastritis should be examined by Pepsinogen I, Pepsinogen II and Gastrin-17 biomarkers.

Notice of Biohit Oyj's extraordinary general meeting

Biohit has settled the dispute concerning a breach of the patent license agreement and therefore specifies its financial guidance for 2021

Biohit Oyj Managers' Trancactions - Elomaa

Biohit Oyj - Managers' Transactions - Siltala

Biohit Oyj - Managers' Transactions - Söderström

Biohit Oyj - Managers' Transactions - Patrakka

Biohit Oyj - Managers' Transactions - Mäki

Biohit Oyj - Managers' Transactions - Hahtela

Biohit Oyj’s Financial Reporting and Annual General Meeting in 2022

Recent clinical validation study confirms the accuracy of the new-generation GastroPanel® test in diagnosis of atrophic gastritis and Helicobacter pylori infection.

Biohit Oyj Board of Directors decided on new option scheme